+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypopharyngeal Cancer - Pipeline Review, H2 2019

  • ID: 4866571
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 311 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Ascenta Therapeutics Inc
  • Biomimetix JV LLC
  • Eisai Co Ltd
  • Incyte Corp
  • Merck & Co Inc
  • Shionogi & Co Ltd
  • MORE
Hypopharyngeal Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2019, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.

Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hypopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypopharyngeal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ascenta Therapeutics Inc
  • Biomimetix JV LLC
  • Eisai Co Ltd
  • Incyte Corp
  • Merck & Co Inc
  • Shionogi & Co Ltd
  • MORE
Introduction
Hypopharyngeal Cancer - Overview
Hypopharyngeal Cancer - Therapeutics Development
Hypopharyngeal Cancer - Therapeutics Assessment
Hypopharyngeal Cancer - Companies Involved in Therapeutics Development
Hypopharyngeal Cancer - Drug Profiles
Hypopharyngeal Cancer - Dormant Projects
Hypopharyngeal Cancer - Discontinued Products
Appendix

List of Tables
Table 1: Number of Products under Development for Hypopharyngeal Cancer, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Hypopharyngeal Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2019
Table 11: Hypopharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2019
Table 12: Hypopharyngeal Cancer - Pipeline by Biomimetix JV LLC, H2 2019
Table 13: Hypopharyngeal Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 14: Hypopharyngeal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2019
Table 15: Hypopharyngeal Cancer - Pipeline by Eisai Co Ltd, H2 2019
Table 16: Hypopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 17: Hypopharyngeal Cancer - Pipeline by Incyte Corp, H2 2019
Table 18: Hypopharyngeal Cancer - Pipeline by Innate Pharma SA, H2 2019
Table 19: Hypopharyngeal Cancer - Pipeline by Merck & Co Inc, H2 2019
Table 20: Hypopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Table 21: Hypopharyngeal Cancer - Pipeline by Shionogi & Co Ltd, H2 2019
Table 22: Hypopharyngeal Cancer - Pipeline by VasGene Therapeutics Inc, H2 2019
Table 23: Hypopharyngeal Cancer - Dormant Projects, H2 2019
Table 24: Hypopharyngeal Cancer - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Hypopharyngeal Cancer, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ascenta Therapeutics Inc
  • AstraZeneca Plc
  • Biomimetix JV LLC
  • Boehringer Ingelheim International GmbH
  • Celldex Therapeutics Inc
  • Eisai Co Ltd
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Innate Pharma SA
  • Merck & Co Inc
  • Ono Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • VasGene Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll